Alzheimer's disease: synapses gone cold

Molecular Neurodegeneration

Tara L Spires-Jones¹  Bradley T Hyman¹  Robert M Koffie² 

[1] Massachusetts General Hospital, Harvard Medical School, 114 16th Street, Charlestown, MA 02129, USA;Harvard Biophysics Program, Building C-2, room 122, 240 Longwood Ave, Boston, MA 02115, USA

关键词: cognitive decline;    long-term potentiation;    long-term depression;    synapse loss;    amyloid-beta;    Alzheimer's disease;   

Others  :  865634
DOI  :  10.1186/1750-1326-6-63

 received in 2011-07-15, accepted in 2011-08-26,  发布年份 2011

【 摘 要 】

Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by insidious cognitive decline and memory dysfunction. Synapse loss is the best pathological correlate of cognitive decline in AD and mounting evidence suggests that AD is primarily a disease of synaptic dysfunction. Soluble oligomeric forms of amyloid beta (Aβ), the peptide that aggregates to form senile plaques in the brain of AD patients, have been shown to be toxic to neuronal synapses both in vitro and in vivo. Aβ oligomers inhibit long-term potentiation (LTP) and facilitate long-term depression (LTD), electrophysiological correlates of memory formation. Furthermore, oligomeric Aβ has also been shown to induce synapse loss and cognitive impairment in animals. The molecular underpinnings of these observations are now being elucidated, and may provide clear therapeutic targets for effectively treating the disease. Here, we review recent findings concerning AD pathogenesis with a particular focus on how Aβ impacts synapses.

【 授权许可】

   
2011 Koffie et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Alzheimer A: Ubereine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 1907, 64:146-148.
• [2]Goedert M, Spillantini MG: A century of Alzheimer's disease. Science 2006, 314(5800):777-781.
• [3]Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA: Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003, 60(8):1119-1122.
• [4]Alzheimer's A, Thies W, Bleiler L: 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011, 7(2):208-244.
• [5]Holtzman DM, Morris JC, Goate AM: Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011, 3(77):77sr71.
• [6]Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
• [7]Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG: Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300(5618):486-489.
• [8]Lansbury PT Jr: Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. Proc Natl Acad Sci USA 1999, 96(7):3342-3344.
• [9]Lansbury PT Jr: In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry 1992, 31(30):6865-6870.
• [10]Tanzi RE, Bertram L: Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005, 120(4):545-555.
• [11]Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC: Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 1998, 43(3):380-383.
• [12]Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, et al.: APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006, 38(1):24-26.
• [13]Bertram L, Lill CM, Tanzi RE: The genetics of Alzheimer disease: back to the future. Neuron 2010, 68(2):270-281.
• [14]Bertram L, Tanzi RE: Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008, 9(10):768-778.
• [15]Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ: Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 2008, 283(33):22529-22540.
• [16]Selkoe DJ, Wolfe MS: In search of gamma-secretase: presenilin at the cutting edge. Proc Natl Acad Sci USA 2000, 97(11):5690-5692.
• [17]Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ: Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature 1999, 398(6727):513-517.
• [18]Murakami K, Irie K, Morimoto A, Ohigashi H, Shindo M, Nagao M, Shimizu T, Shirasawa T: Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J Biol Chem 2003, 278(46):46179-46187.
• [19]Tsubuki S, Takaki Y, Saido TC: Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation. Lancet 2003, 361(9373):1957-1958.
• [20]Games D, Adams D, Alessandrini R, Barbour R, Borthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F [beta]-amyloid precursor protein. Nature 1995, 373(6514):523-527.
• [21]Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L: High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 2000, 20(11):4050-4058.
• [22]Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440(7082):352-357.
• [23]Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004, 43(3):321-332.
• [24]Lemere CA, Masliah E: Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010, 6(2):108-119.
• [25]Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002, 298(5594):789-791.
• [26]Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA, McKeel DW, Morris JC: Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001, 56(1):127-129.
• [27]DeKosky ST, Scheff SW: Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol 1990, 27(5):457-464.
• [28]Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30(4):572-580.
• [29]Davies CA, Mann DM, Sumpter PQ, Yates PO: A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci 1987, 78(2):151-164.
• [30]Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ: Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68(18):1501-1508.
• [31]DeKosky ST, Scheff SW, Styren SD: Structural correlates of cognition in dementia: quantification and assessment of synapse change. Neurodegeneration 1996, 5(4):417-421.
• [32]Coleman PD, Yao PJ: Synaptic slaughter in Alzheimer's disease. Neurobiol Aging 2003, 24(8):1023-1027.
• [33]Lanz TA, Carter DB, Merchant KM: Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 2003, 13(3):246-253.
• [34]Moolman DL, Vitolo OV, Vonsattel JP, Shelanski ML: Dendrite and dendritic spine alterations in Alzheimer models. J Neurocytol 2004, 33(3):377-387.
• [35]Tsai J, Grutzendler J, Duff K, Gan WB: Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci 2004, 7(11):1181-1183.
• [36]Spires TL, Hannan AJ: Nature, nurture and neurology: gene-environment interactions in neurodegenerative disease. FEBS Anniversary Prize Lecture delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FEBS J 2005, 272(10):2347-2361.
• [37]Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al.: Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 2009, 106(10):4012-4017.
• [38]Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ: Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 1999, 19(20):8876-8884.
• [39]Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB: Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999, 274(36):25945-25952.
• [40]Harper JD, Wong SS, Lieber CM, Lansbury PT: Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997, 4(2):119-125.
• [41]Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, et al.: Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998, 95(11):6448-6453.
• [42]Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr: Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418(6895):291.
• [43]Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ: The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 2000, 39(35):10831-10839.
• [44]Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880):535-539.
• [45]Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-[beta] protein assembly in the brain impairs memory. 2006, 440(7082):352-357.
• [46]Enya M, Morishima-Kawashima M, Yoshimura M, Shinkai Y, Kusui K, Khan K, Games D, Schenk D, Sugihara S, Yamaguchi H, et al.: Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am J Pathol 1999, 154(1):271-279.
• [47]Funato H, Enya M, Yoshimura M, Morishima-Kawashima M, Ihara Y: Presence of sodium dodecyl sulfate-stable amyloid beta-protein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am J Pathol 1999, 155(1):23-28.
• [48]Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, Woods AS, Cotter RJ, Tuohy JM, Krafft GA, et al.: Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 1996, 271(34):20631-20635.
• [49]Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, et al.: Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 2002, 924(2):133-140.
• [50]Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ: Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006, 572(Pt 2):477-492.
• [51]Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL: Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27(11):2866-2875.
• [52]Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al.: Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14(8):837-842.
• [53]Townsend M, Mehta T, Selkoe DJ: Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 2007, 282(46):33305-33312.
• [54]Walsh DM, Townsend M, Podlisny MB, Shankar GM, Fadeeva JV, El Agnaf O, Hartley DM, Selkoe DJ: Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 2005, 25(10):2455-2462.
• [55]Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D: Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009, 62(6):788-801.
• [56]Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ: Use-dependent effects of amyloidogenic fragments of (beta)-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J Neurosci 2001, 21(4):1327-1333.
• [57]Palop JJ, Mucke L: Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13(7):812-818.
• [58]Kemp N, Bashir ZI: Long-term depression: a cascade of induction and expression mechanisms. Prog Neurobiol 2001, 65(4):339-365.
• [59]Wu J, Rowan MJ, Anwyl R: Long-term potentiation is mediated by multiple kinase cascades involving CaMKII or either PKA or p42/44 MAPK in the adult rat dentate gyrus in vitro. J Neurophysiol 2006, 95(6):3519-3527.
• [60]Harney SC, Rowan M, Anwyl R: Long-term depression of NMDA receptor-mediated synaptic transmission is dependent on activation of metabotropic glutamate receptors and is altered to long-term potentiation by low intracellular calcium buffering. J Neurosci 2006, 26(4):1128-1132.
• [61]Anwyl R: Induction and expression mechanisms of postsynaptic NMDA receptor-independent homosynaptic long-term depression. Prog Neurobiol 2006, 78(1):17-37.
• [62]Citri A, Malenka RC: Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 2008, 33(1):18-41.
• [63]Kullmann DM, Lamsa KP: Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci 2007, 8(9):687-699.
• [64]Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT: Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science 2004, 304(5673):1021-1024.
• [65]Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY: Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature 1994, 368(6467):144-147.
• [66]Chen N, Luo T, Raymond LA: Subtype-dependence of NMDA receptor channel open probability. J Neurosci 1999, 19(16):6844-6854.
• [67]Sprengel R, Suchanek B, Amico C, Brusa R, Burnashev N, Rozov A, Hvalby O, Jensen V, Paulsen O, Andersen P, et al.: Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. Cell 1998, 92(2):279-289.
• [68]Sheng M, Pak DT: Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu Rev Physiol 2000, 62:755-778.
• [69]Matsuzaki M, Honkura N, Ellis-Davies GC, Kasai H: Structural basis of long-term potentiation in single dendritic spines. Nature 2004, 429(6993):761-766.
• [70]Nagerl UV, Eberhorn N, Cambridge SB, Bonhoeffer T: Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron 2004, 44(5):759-767.
• [71]Zhou Q, Homma KJ, Poo MM: Shrinkage of dendritic spines associated with long-term depression of hippocampal synapses. Neuron 2004, 44(5):749-757.
• [72]Bastrikova N, Gardner GA, Reece JM, Jeromin A, Dudek SM: Synapse elimination accompanies functional plasticity in hippocampal neurons. Proc Natl Acad Sci USA 2008, 105(8):3123-3127.
• [73]Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R: Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004, 24(13):3370-3378.
• [74]Tackenberg C, Brandt R: Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci 2009, 29(46):14439-14450.
• [75]Li Z, Jo J, Jia JM, Lo SC, Whitcomb DJ, Jiao S, Cho K, Sheng M: Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell 2010, 141(5):859-871.
• [76]Mayr BM, Canettieri G, Montminy MR: Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proc Natl Acad Sci USA 2001, 98(19):10936-10941.
• [77]Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001, 2(8):599-609.
• [78]Cummings BJ, Pike CJ, Shankle R, Cotman CW: Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996, 17(6):921-933.
• [79]Mulkey RM, Endo S, Shenolikar S, Malenka RC: Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature 1994, 369(6480):486-488.
• [80]Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB: beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000, 275(8):5626-5632.
• [81]Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, et al.: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8(8):1051-1058.
• [82]Nicoll RA, Malenka RC: Expression mechanisms underlying NMDA receptor-dependent long-term potentiation. Ann N Y Acad Sci 1999, 868:515-525.
• [83]Jo J, Whitcomb DJ, Olsen KM, Kerrigan TL, Lo SC, Bru-Mercier G, Dickinson B, Scullion S, Sheng M, Collingridge G, et al.: Abeta(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3beta. Nat Neurosci 2011, 14(5):545-547.
• [84]D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, et al.: Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 2011, 14(1):69-76.
• [85]Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R: AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 2006, 52(5):831-843.
• [86]Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H, et al.: Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 2009, 29(41):12957-12969.
• [87]Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008, 59(2):214-225.
• [88]Wen Z, Guirland C, Ming GL, Zheng JQ: A CaMKII/calcineurin switch controls the direction of Ca(2+)-dependent growth cone guidance. Neuron 2004, 43(6):835-846.
• [89]Slepnev VI, Ochoa GC, Butler MH, Grabs D, De Camilli P: Role of phosphorylation in regulation of the assembly of endocytic coat complexes. Science 1998, 281(5378):821-824.
• [90]Dineley KT, Hogan D, Zhang WR, Taglialatela G: Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 2007, 88(2):217-224.
• [91]Wu HY, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z, Spires-Jones T, Xie H, Arbel-Ornath M, Grosskreutz CL, et al.: Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 2010, 30(7):2636-2649.
• [92]Rozkalne A, Hyman BT, Spires-Jones TL: Calcineurin inhibition with FK506 ameliorates dendritic spine density deficits in plaque-bearing Alzheimer model mice. Neurobiol Dis 2011, 41(3):650-654.
• [93]Spires-Jones TL, Kay K, Matsouka R, Rozkalne A, Betensky RA, Hyman BT: Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain. Neurosci Lett 2011, 487(3):260-263.
• [94]Zhang Y, Kurup P, Xu J, Carty N, Fernandez SM, Nygaard HB, Pittenger C, Greengard P, Strittmatter SM, Nairn AC, et al.: Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 2010, 107(44):19014-19019.
• [95]Kurup P, Zhang Y, Venkitaramani DV, Xu J, Lombroso PJ: The role of STEP in Alzheimer's disease. Channels (Austin) 2010, 4(5):347-350.
• [96]Kurup P, Zhang Y, Xu J, Venkitaramani DV, Haroutunian V, Greengard P, Nairn AC, Lombroso PJ: Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci 2010, 30(17):5948-5957.
• [97]Takasu MA, Dalva MB, Zigmond RE, Greenberg ME: Modulation of NMDA receptor-dependent calcium influx and gene expression through EphB receptors. Science 2002, 295(5554):491-495.
• [98]Henderson JT, Georgiou J, Jia Z, Robertson J, Elowe S, Roder JC, Pawson T: The receptor tyrosine kinase EphB2 regulates NMDA-dependent synaptic function. Neuron 2001, 32(6):1041-1056.
• [99]Dalva MB, Takasu MA, Lin MZ, Shamah SM, Hu L, Gale NW, Greenberg ME: EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 2000, 103(6):945-956.
• [100]Chen Y, Fu AK, Ip NY: Bidirectional signaling of ErbB and Eph receptors at synapses. Neuron Glia Biol 2008, 4(3):211-221.
• [101]Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, et al.: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011, 469(7328):47-52.
• [102]Simon AM, de Maturana RL, Ricobaraza A, Escribano L, Schiapparelli L, Cuadrado-Tejedor M, Perez-Mediavilla A, Avila J, Del Rio J, Frechilla D: Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis 2009, 17(4):773-786.
• [103]Vitolo OV, Sant'Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M: Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 2002, 99(20):13217-13221.
• [104]Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ: Soluble A{beta} Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors. J Neurosci 2011, 31(18):6627-6638.
• [105]Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008, 192(1):106-113.
• [106]Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT: Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 2005, 25(31):7278-7287.
• [107]Rozkalne A, Spires-Jones TL, Stern EA, Hyman BT: A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res 2009, 1280:178-185.
• [108]Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, Schenk D, Hyman BT: Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis 2009, 33(2):213-220.
• [109]Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, Kholodenko D, Malenka RC, Nicoll RA, Mucke L: Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 1999, 96(6):3228-3233.
• [110]Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R: APP processing and synaptic function. Neuron 2003, 37(6):925-937.
• [111]Ferrer I, Gullotta F: Down's syndrome and Alzheimer's disease: dendritic spine counts in the hippocampus. Acta Neuropathol 1990, 79(6):680-685.
• [112]Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR: Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol 2000, 2(9):628-636.
• [113]O'Hare E, Weldon DT, Mantyh PW, Ghilardi JR, Finke MP, Kuskowski MA, Maggio JE, Shephard RA, Cleary J: Delayed behavioral effects following intrahippocampal injection of aggregated A beta (1-42). Brain Res 1999, 815(1):1-10.
• [114]Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8(1):79-84.
• [115]Cleary J, Hittner JM, Semotuk M, Mantyh P, O'Hare E: Beta-amyloid(1-40) effects on behavior and memory. Brain Res 1995, 682(1-2):69-74.
• [116]Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22(15):6331-6335.
• [117]Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, et al.: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5(5):452-457.
• [118]Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, Spooner ET, Jiang L, Anwyl R, Selkoe DJ, et al.: Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005, 11(5):556-561.
• [119]McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, et al.: Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006, 12(7):801-808.
• [120]Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL: Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003, 100(18):10417-10422.
• [121]Puzzo D, Privitera L, Fa M, Staniszewski A, Hashimoto G, Aziz F, Sakurai M, Ribe EM, Troy CM, Mercken M, et al.: Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011, 69(5):819-830.
• [122]Puzzo D, Privitera L, Leznik E, Fa M, Staniszewski A, Palmeri A, Arancio O: Picomolar Amyloid-{beta} Positively Modulates Synaptic Plasticity and Memory in Hippocampus. 10.1523/JNEUROSCI.2692-08.2008. J Neurosci 2008, 28(53):14537-14545.
• [123]Venkitaramani DV, Chin J, Netzer WJ, Gouras GK, Lesne S, Malinow R, Lombroso PJ: Beta-amyloid modulation of synaptic transmission and plasticity. J Neurosci 2007, 27(44):11832-11837.
• [124]Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I: Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci 2009, 12(12):1567-1576.
• [125]Micheva KD, O'Rourke N, Busse B, Smith SJ: Array tomography: production of arrays. Cold Spring Harb Protoc 2010., 2010(11) pdb prot 5524
• [126]Micheva KD, Smith SJ: Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron 2007, 55(1):25-36.
• [127]Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM: Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 2006, 281(7):4292-4299.
• [128]Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM: Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48(6):913-922.
• [129]Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM: Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 2008, 58(1):42-51.
• [130]Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, et al.: In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci 2003, 23(26):8844-8853.
• [131]Ting JT, Kelley BG, Lambert TJ, Cook DG, Sullivan JM: Amyloid precursor protein overexpression depresses excitatory transmission through both presynaptic and postsynaptic mechanisms. Proc Natl Acad Sci USA 2007, 104(1):353-358.
• [132]Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J: Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006, 26(27):7212-7221.
• [133]Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V: High ability of apolipoprotein E4 to stabilize amyloid-{beta} peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J 2011, 25(5):1585-1595.
• [134]Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457(7233):1128-1132.
• [135]Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, Walsh DM, Rowan MJ: Alzheimer's Disease Brain-Derived Amyloid-{beta}-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein. J Neurosci 2011, 31(20):7259-7263.
• [136]Kessels HW, Nguyen LN, Nabavi S, Malinow R: The prion protein as a receptor for amyloid-beta. Nature 2010, 466(7308):E3-4; discussion E4-5.
• [137]Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, Tapella L, Colombo L, Manzoni C, Borsello T, et al.: Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 2010, 107(5):2295-2300.
• [138]Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A: Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010, 2(8):306-314.
• [139]Renner M, Lacor PN, Velasco PT, Xu J, Contractor A, Klein WL, Triller A: Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron 2010, 66(5):739-754.
• [140]Hyman BT: Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease. Arch Neurol 2011.
• [141]Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT: Are Tangles as Toxic as They Look? J Mol Neurosci 2011.
• [142]Spires-Jones TL, de Calignon A, Meyer-Luehmann M, Bacskai BJ, Hyman BT: Monitoring protein aggregation and toxicity in Alzheimer's disease mouse models using in vivo imaging. Methods 2011, 53(3):201-207.